IRadimed Corporation Awarded HealthTrust Purchasing Group Contract for its MRidium MRI Infusion Pump System

WINTER PARK, Fla., April 17, 2013 -- HealthTrust Purchasing Group (HealthTrust), one of the largest health care supply contracting companies in the United States, has awarded IRadimed Corporation a contract for its MRidium™ MRI Infusion Pump Systems. Effective April 1, 2013, the agreement makes the MRidium™ Systems available to the more than 1,400 not-for-profit and for-profit acute care facility members served by HealthTrust. The MRidium™ System was awarded the contract under HealthTrust's MR Compatible IV Pump category. This new agreement offers a broad base of new customers for IRadimed to serve and grow its current strong base of MRidium™ MRI infusion pumps in the U.S. market.

IRadimed's MRidium™ infusion pump is the only non-magnetic MRI IV pump solution currently available on the market today and is built from the ground up to deliver accurately and safely in the MRI area. "It is critical to have products which have been designed with the utmost care and thorough insight of this harsh and potentially dangerous environment," said Roger Susi, president and founder of IRadimed Corporation.

The MRidium™3860 MRI Infusion System offers optional integrated Masimo SET® SpO2 capability for continuous monitoring of patients from the ICU, NICU, Neurology and other areas of the hospital right into the MRI Suite. The 3860 System also offers an expanded drug library with DERS (Dose Error Reduction System), which helps prevent medication entry errors while programming infusions, and provides the patient safety features that are quickly becoming the standard in infusion therapy in general patient care areas.

The MRidium™ System offers a modular second channel, which when attached to the 3860 IV Pump, allows for delivery of two medications simultaneously during patient scans. An optional fully featured wireless remote control monitor is also available that has true plug and play capabilities, requiring no installation. A full range of available infusion sets are also available to provide the clinical flexibility needed in the demanding MRI environment.

About IRadimed Corporation

IRadimed Corporation is a leader in MRI safe products and infusion therapy. Our founder is the pioneering developer of both the world's first and best selling MRI compatible monitoring system and the only Non Magnetic IV Pumps designed specifically for use in the MRI environment. IRadimed's staff has a combined 70+ years of developing MRI safe products. The MRidium™ Infusion System has full benefit of the experience and attention to details so important to the development of quality equipment which can be safely used in the MRI setting. For more information please visit www.iradimed.comMRidiumis a Trademark of IRadimed Corporation.

About HealthTrust Purchasing Group

HealthTrust Purchasing Group (www.healthtrustpg.com) is committed to strengthening provider performance and clinical excellence through an aligned membership model and the delivery of total cost management solutions, including supply chain solutions and a contract and service portfolio unparalleled in quality, scope and value. HealthTrust serves 1,400 acute care facilities, 800 ambulatory surgery centers and members in more than 10,600 other locations including physician practices, long-term care and alternate care sites. Headquartered in Brentwood, Tenn., HealthTrust is closely integrated with the provider-proven capabilities of Parallon Business Solutions (www.parallon.net) which include workforce management solutions, revenue cycle and business process expertise and technology solutions.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.